These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2893535)

  • 1. Qualities of an ideal beta-adrenoceptor antagonist and comparison of existing agents with a new cardioselective hydrophilic vasodilator beta-adrenoceptor antagonist, celiprolol.
    Opie LH
    Am J Cardiol; 1988 Feb; 61(5):8C-13C. PubMed ID: 2893535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celiprolol: a new beta adrenoceptor antagonist with novel ancillary properties.
    Pruss TP; Khandwala A; Wolf PS; Grebow P; Wong L
    J Cardiovasc Pharmacol; 1986; 8 Suppl 4():S29-32. PubMed ID: 2427849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive therapy with celiprolol: a new cardioselective beta blocker.
    Norris RJ
    Am J Cardiol; 1988 Feb; 61(5):14C-22C. PubMed ID: 2893531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris.
    Riddell JG; Shanks RG; Brogden RN
    Drugs; 1987 Oct; 34(4):438-58. PubMed ID: 2890513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacology of celiprolol: a cardioselective beta-adrenergic antagonist and mild vasodilator.
    Perrone MH; Barrett JA
    Am Heart J; 1991 Feb; 121(2 Pt 2):677-83. PubMed ID: 1671187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.
    Milne RJ; Buckley MM
    Drugs; 1991 Jun; 41(6):941-69. PubMed ID: 1715268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.
    Dunn CJ; Spencer CM
    Drugs Aging; 1995 Nov; 7(5):394-411. PubMed ID: 8573993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celiprolol and the heart.
    Taylor SH
    Am J Cardiol; 1988 Feb; 61(5):34C-40C. PubMed ID: 2893532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of vasodilatory beta-blocking drugs.
    Shanks RG
    Am Heart J; 1991 Mar; 121(3 Pt 2):1006-11. PubMed ID: 1671724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No evidence for a direct vasodilatory effect of celiprolol on human vasculature in vivo or in vitro.
    Hughes A; Martin G; Goldberg P; Thom S; Sever P
    J Cardiovasc Pharmacol; 1987 Nov; 10(5):589-92. PubMed ID: 2447410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic studies on the "bronchosparing" activity of celiprolol, a cardioselective beta-adrenoceptor antagonist.
    Van Inwegen RG; Khandwala A; Gordon RJ; Sutherland CA; Wolf P; Pruss TP
    Arch Int Pharmacodyn Ther; 1986 Nov; 284(1):127-44. PubMed ID: 2881517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of celiprolol, a new cardioselective beta 1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly.
    Lamon KD
    Cardiovasc Drugs Ther; 1991 Jan; 4 Suppl 6():1291-5. PubMed ID: 1672605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celiprolol, a potent cardioselective beta 1-adrenoceptor antagonist with mild alpha 2-adrenoceptor antagonist properties.
    Wolf PS; Pruss TP; Rand MJ; Smith RD; Mann WS; Romano DV
    J Hypertens Suppl; 1985 Dec; 3(3):S195-7. PubMed ID: 2908816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of cardioselective vasodilating beta-blockers on lipids.
    Hunninghake DB
    Am Heart J; 1991 Mar; 121(3 Pt 2):1029-32. PubMed ID: 1671728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of celiprolol.
    Louis WJ; Drummer OH; Tung LH
    Cardiovasc Drugs Ther; 1991 Jan; 4 Suppl 6():1281-5. PubMed ID: 1672604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of celiprolol (REV 5320), a new cardioselective beta-adrenoceptor antagonist, on in vitro adenylate cyclase, alpha- and beta-adrenergic receptor binding and lipolysis.
    Van Inwegen RG; Khandwala A; Weinryb I; Pruss TP; Neiss E; Sutherland CA
    Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):40-55. PubMed ID: 6151380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease.
    Fogari R; Zoppi A; Tettamanti F; Poletti L; Rizzardi G; Fiocchi G
    Cardiovasc Drugs Ther; 1990 Aug; 4(4):1145-9. PubMed ID: 1982059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of celiprolol in the elderly hypertensive patient.
    Taylor SH
    Am Heart J; 1991 Mar; 121(3 Pt 2):1020-9. PubMed ID: 1671727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute hemodynamic effects of celiprolol.
    Donaldson RM; Williams LA; Lee EH
    Am J Cardiol; 1988 Feb; 61(5):49C-51C. PubMed ID: 2963526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the antihypertensive mechanisms of beta-adrenoceptor antagonists in relation to intrinsic sympathomimetic activity, cardioselectivity and hydrophilicity.
    Man in't Veld AJ; Schalekamp MA
    J Pharmacol; 1983; 14 Suppl 2():69-104. PubMed ID: 6138473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.